Attached files
| file | filename |
|---|---|
| 10-Q - RegenoCELL Therapeutics, Inc. | v205535_10q.htm |
| EX-31.1 - RegenoCELL Therapeutics, Inc. | v205535_ex31-1.htm |
Exhibit
32.1
REGENOCELL
THERAPEUTICS, INC.
CERTIFICATION
PURSUANT TO
18 U.S.C.
SECTION 1350
AS
ADOPTED PURSUANT TO SECTION 906
OF THE
SARBANNES-OXLEY ACT OF 2002
In
connection with the quarterly report of RegenoCELL Therapeutics, Inc. (the
“Company”) on Form 10Q for the quarter ended September 30, 2010 (the “Report”),
I, James F. Mongiardo, Chief Executive Officer and Chief Financial Officer of
the Company, certify, pursuant to Section 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my
knowledge:
(1) The
Report fully complies with the requirements of Section 13 (a) or 15 (d) of the
Securities Exchange Act of 1934; and
(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
|
/s/
|
James F. Mongiardo
|
|
|
James
F. Mongiardo
|
||
|
Chief
Executive Officer
|
||
|
and
|
||
|
Chief
Financial Officer
|
||
|
December
13, 2010
|